ABEONA THERAPEUTICS INC.

8-K · form8-k.htm

0000318306

 2026-06-11
 2026-06-11

 iso4217:USD

 xbrli:shares

 iso4217:USD

 xbrli:shares

  

  

  

 UNITED
STATES

 SECURITIES
AND EXCHANGE COMMISSION

 Washington,
DC 20549

  

 FORM
 8-K

  

 CURRENT
REPORT

 PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

 Date
of report (Date of earliest event reported): June 11,
2026

  

 ABEONA
THERAPEUTICS INC.

 (Exact
name of registrant as specified in its charter)

  

 Delaware
  
 001-15771
  
 83-0221517

 (State or other jurisdiction
  
 (Commission
  
 (I.R.S. Employer

 of incorporation)
  
 File Number)
  
 Identification No.)

  

 6555
Carnegie Ave , 4th
Floor

 Cleveland ,
 OH 44103

 (Address
of principal executive offices) (Zip Code)

  

 (646)
 813-4701

 (Registrant’s
telephone number, including area code)

  

 N
/A

 (Former
name or former address, if changed since last report)

  

 Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):

  

 ☐
 Written communications pursuant
 to Rule 425 under the Securities Act (17 CFR 230.425)

  

 ☐
 Soliciting material pursuant
 to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

 ☐
 Pre-commencement communications
 pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))

  

 ☐
 Pre-commencement communications
 pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 Title
 of Each Class
  
 Trading
 Symbol
  
 Name
 of each exchange on which registered

 Common
 Stock, $0.01 par value
  
 ABEO
  
 The
 Nasdaq Capital
 Market

  

 Securities
registered pursuant to Section 12(b) of the Act:

  

 Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging
growth company ☐

  

 If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  

  

  

  

  

  

 Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.

  

 On
June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the
“Company”) effective immediately. In connection with his resignation, Mr. Amoroso also resigned from the Nominating and Corporate
Governance Committee of the Board on which he served. Mr. Amoroso’s resignation was not the result of any disagreement with the
Company on any matter relating to the Company’s operations, policies or practices but solely for personal reasons.

  

  

  

  

 SIGNATURE

  

 Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

  

  
 Abeona Therapeutics Inc.

  
 (Registrant)

  
  
  

  
 By:
 /s/ Joseph Vazzano

  
 Name:
 Joseph Vazzano

  
 Title:
 Chief Financial Officer

  

Date: June 11, 2026